Pre-treatment biopsychosocial predictors of chemotherapy-induced peripheral neuropathy trajectories in people with breast cancer

Chemotherapy-induced peripheral neuropathy (CIPN) affects many people receiving taxane treatment for breast cancer. Symptom trajectories vary, with some recovering, and others experiencing persistent, or delayed worsening (coasting) symptoms. The prevalence and predictors of these trajectories remain unclear. This study identified the prevalence and biopsychosocial predictors of CIPN persistence, improvement, and coasting within 3 months post-treatment. This secondary analysis included participants treated with taxanes for stage I–III breast cancer who completed the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity-4 (FACT/GOG-NTX-4) at baseline, post-chemotherapy, and 3 months later. A minimally important difference (MID) from baseline on the FACT/GOG-NTX-4 defined persistence, improvement, coasting, and no MID-CIPN (below the MID threshold at each assessment) trajectories. Baseline assessments included self-reported pain/well-being, sensory, balance, and lower limb physical functioning measures, and sociodemographic and treatment data were collected. Among 102 participants (51.57 ± 11.24 years), persistence occurred in 34.3%, improvement in 25.5%, coasting in 6.9%, and no MID-CIPN in 33.3%. Compared to no MID-CIPN, older age (OR = 1.120; 95% CI 1.026–1.222), higher expected pain (OR = 1.630; 95% CI 1.082–2.456), and cold hyperalgesia at the foot (OR = 1.130; 95% CI 1.018–1.254) predicted persistence. Greater fatigue predicted improvement (OR = 0.904; 95% CI 0.845–0.968). No predictors were identified for coasting. CIPN trajectories are heterogeneous. Age and pre-treatment pain expectations, cold hyperalgesia, and fatigue differentiate patients with persistent CIPN and those likely to improve from those with no CIPN. Early identification of individuals at risk for persistent neurotoxicity may support risk stratification and guide targeted supportive care strategies.

Authors

Institutions

Publication Details

Journal
Journal of Cancer Survivorship
Published
2026-11-21
DOI
https://doi.org/10.1007/s11764-026-02157-4
Primary Topic
Cancer Treatment and Pharmacology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pre-treatment biopsychosocial predictors of chemotherapy-induced peripheral neuropathy trajectories in people with breast cancer

Maud Bouffard, Lynn R. Gauthier, Lucia Gagliese, Jennifer S. Gewandter et al.
2 links
Journal of Cancer Survivorship
Cancer Treatment and Pharmacology
article

Pre-treatment biopsychosocial predictors of chemotherapy-induced peripheral neuropathy trajectories in people with breast cancer

Maud Bouffard, Lynn R. Gauthier, Lucia Gagliese, Jennifer S. Gewandter, Anne R. Dionne, Robert H. Dworkin, Frédérique Therrien, Sarah Béland, Sophie Lauzier, Philip L. Jackson, Antoine Frasie, Julie Lemieux, Charles-Antoine Auger, Josée Savard
article en

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) affects many people receiving taxane treatment for breast cancer. Symptom trajectories vary, with some recovering, and others experiencing persistent, or delayed worsening (coasting) symptoms. The prevalence and predictors of these trajectories remain unclear. This study identified the prevalence and biopsychosocial predictors of CIPN persistence, improvement, and coasting within 3 months post-treatment. This secondary analysis included participants treated with taxanes for stage I–III breast cancer who completed the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity-4 (FACT/GOG-NTX-4) at baseline, post-chemotherapy, and 3 months later. A minimally important difference (MID) from baseline on the FACT/GOG-NTX-4 defined persistence, improvement, coasting, and no MID-CIPN (below the MID threshold at each assessment) trajectories. Baseline assessments included self-reported pain/well-being, sensory, balance, and lower limb physical functioning measures, and sociodemographic and treatment data were collected. Among 102 participants (51.57 ± 11.24 years), persistence occurred in 34.3%, improvement in 25.5%, coasting in 6.9%, and no MID-CIPN in 33.3%. Compared to no MID-CIPN, older age (OR = 1.120; 95% CI 1.026–1.222), higher expected pain (OR = 1.630; 95% CI 1.082–2.456), and cold hyperalgesia at the foot (OR = 1.130; 95% CI 1.018–1.254) predicted persistence. Greater fatigue predicted improvement (OR = 0.904; 95% CI 0.845–0.968). No predictors were identified for coasting. CIPN trajectories are heterogeneous. Age and pre-treatment pain expectations, cold hyperalgesia, and fatigue differentiate patients with persistent CIPN and those likely to improve from those with no CIPN. Early identification of individuals at risk for persistent neurotoxicity may support risk stratification and guide targeted supportive care strategies.

Journal of Cancer Survivorship
University of Toronto (CA), York University (CA), University of Rochester Medical Center (US), Centre hospitalier universitaire de Québec (CA), Michel-Sarrazin (CA), Sinai Health System (CA), Université Laval (CA), Centre de recherche du CHU de Québec-Université Laval (CA), Centre interdisciplinaire de recherche en réadaptation et intégration sociale (CA), Centre de recherche CERVO (CA), University of Rochester (US), Université du Québec à Trois-Rivières (CA)
Pfizer, Canadian Institutes of Health Research
Good health and well-being
Cancer Treatment and Pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon